These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2005-000941-12 Phase III randomised, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV me... 2009-01-08 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-016839-35 A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma 2017-12-05 bad-data
Reported results 2009-016840-38 A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma 2015-09-04 due-trials
Reported results 2012-000128-16 A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone Versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma 2018-02-05 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-005283-97 A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple Myeloma 2016-11-04 bad-data
Exempt 2013-001169-18 Phase 1b/2, Multicenter, Open-label Study of Oprozomib and 2019-06-25 not-yet-due
Exempt, with results 2013-002125-27 Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma 2015-08-31 not-yet-due
Exempt, with results 2013-002597-44 Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer 2017-05-04 not-yet-due
Other 2014-001633-84 Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblasti... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-005325-12 A Randomized, Open-label, Phase 3 Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination with Dexamethasone, Comparing Once-weekly versus Twice-weekly Car... 2019-01-07 bad-data